Hester Biosciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹100Cr
- +22% YoY
- +29.9% QoQ
- Net profit
- ₹17Cr
- +750% YoY
- +88.9% QoQ
- Margin
- 34%
- +11 pp YoY
- +11 pp QoQ
Guidance rank: #35 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.
From Hester Biosciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term.
- Poultry Healthcare showed strong growth, with sustained demand and 41% Q4 growth, indicating ongoing momentum.
- Focus on expanding market penetration both domestically and in export markets, especially in Africa, with strategic emphasis on biologicals and vaccine portfolio strengthening.
- Capacity expansions like Fill-Finish and BSL-3 facilities enhance product capacity and provide scalability without immediate need for new capital expenditure.
2 more points from Hester Biosciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.
- Optimization initiatives for BSL-3 facility are ongoing to improve utilization efficiency and operating costs aligned with current operational and scale-up needs.
- No definitive plan to allocate further capital expenditure currently, but evolving regulatory requirements and new technologies may necessitate future investments.
- Company aims to optimize utilization of installed capacities rather than immediately expanding further.
- Strategic focus includes strengthening biologicals portfolio, improving capacity utilization, and expanding market penetration.
2 more points from Hester Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Animal Healthcare division faced delays in tender-led immunization programs during FY26 due to timing issues beyond the company's control.
- Execution of tender orders started picking up from Q4 FY26 onwards.
- Demand visibility for Animal Healthcare tender programs remains strong but dependent on country-level rollout schedules.
2 more points from Hester Biosciences Ltd's call on order book
Create a free account to keep reading this call
Hester Biosciences Ltd — Quarterly revenue & net profit
Hester Biosciences Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 100 | 82 | +22% | 77 | +29.9% |
| Operating profit (EBITDA) | 34 | 19 | +78.9% | 18 | +88.9% |
| Operating margin | 34% | 23% | +11 pp | 23% | +11 pp |
| Profit before tax | 25 | 4 | +525% | 14 | +78.6% |
| Net profit (PAT) | 17 | 2 | +750% | 9 | +88.9% |
| EPS (₹) | 18.78 | 1.52 | +1135.5% | 10.31 | +82.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹98 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Biosciences Ltd Q4 FY26 results?
The company expects a recovery and pickup in the Animal Healthcare division starting Q4 FY26, aiming for a more balanced revenue mix closer to a 50:50 split between Poultry and Animal Health segments in the long term. Focus on strengthening Animal Health division and biologicals, expected to pick up alongside Poultry segment.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Hester Biosciences capitalized Fill-Finish and BSL-3 facilities during the year as part of manufacturing and infrastructure expansion to enhance capacity and flexibility for domestic and export markets.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
